<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 25 Jan 2021 23:32:40 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程</title><link>https://mp.weixin.qq.com/s/15DC3Y1g9ZB6xu_Z1E-oQg</link><description></description><content:encoded><![CDATA[《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:59:45 +0800</pubDate></item><item><title>首个狼疮肾炎口服疗法！FDA批准Voclosporin上市</title><link>https://mp.weixin.qq.com/s/YenM4eG3JNjr5FCDF3rJqg</link><description></description><content:encoded><![CDATA[首个狼疮肾炎口服疗法！FDA批准Voclosporin上市]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:59:45 +0800</pubDate></item><item><title>又一新兴免疫检查点遭重创，葛兰素史克放弃LAG3单抗开发</title><link>https://mp.weixin.qq.com/s/1wfwwoYMIE3w94lSbRlFrQ</link><description></description><content:encoded><![CDATA[又一新兴免疫检查点遭重创，葛兰素史克放弃LAG3单抗开发]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:59:45 +0800</pubDate></item><item><title>常见非IgG样双抗</title><link>https://mp.weixin.qq.com/s/-qvy2r0OA9B4Vr2jxPkmpg</link><description></description><content:encoded><![CDATA[常见非IgG样双抗]]></content:encoded><pubDate>Mon, 25 Jan 2021 17:59:45 +0800</pubDate></item><item><title>靶点药讯45|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/iJq9iHCMsGGpUQvJ_HHEfQ</link><description></description><content:encoded><![CDATA[靶点药讯45|纵览全球药物靶点动态]]></content:encoded><pubDate>Sun, 24 Jan 2021 11:28:36 +0800</pubDate></item><item><title>不同肿瘤的免疫微环境差异，决定免疫治疗效果</title><link>https://mp.weixin.qq.com/s/XuYBJg0lreLITRa6NFf1Iw</link><description></description><content:encoded><![CDATA[不同肿瘤的免疫微环境差异，决定免疫治疗效果]]></content:encoded><pubDate>Sun, 24 Jan 2021 11:28:36 +0800</pubDate></item><item><title>166笔交易，累计1310亿美元 | 2020年生物制药行业交易解析</title><link>https://mp.weixin.qq.com/s/ls9o8J_8014JaTa-0sbWCw</link><description></description><content:encoded><![CDATA[166笔交易，累计1310亿美元 | 2020年生物制药行业交易解析]]></content:encoded><pubDate>Sat, 23 Jan 2021 10:09:19 +0800</pubDate></item><item><title>专利问题迫在眉睫，罗氏重磅炸弹IPF药物获得优先审查</title><link>https://mp.weixin.qq.com/s/VOKKO1fiIGsSYclLZ2Bm3w</link><description></description><content:encoded><![CDATA[专利问题迫在眉睫，罗氏重磅炸弹IPF药物获得优先审查]]></content:encoded><pubDate>Sat, 23 Jan 2021 10:09:19 +0800</pubDate></item><item><title>首款且唯一，欧盟委员会批准首款CD123靶向疗法上市</title><link>https://mp.weixin.qq.com/s/8nUutbkFjV9nH1WgBtXJGQ</link><description></description><content:encoded><![CDATA[首款且唯一，欧盟委员会批准首款CD123靶向疗法上市]]></content:encoded><pubDate>Fri, 22 Jan 2021 12:28:42 +0800</pubDate></item><item><title>药明康德2020年净利润同比增长50％到60％，海外客户订单较快增长</title><link>https://mp.weixin.qq.com/s/xiqgga8Qpfhf6v2PaOzhkw</link><description></description><content:encoded><![CDATA[药明康德2020年净利润同比增长50％到60％，海外客户订单较快增长]]></content:encoded><pubDate>Fri, 22 Jan 2021 12:28:42 +0800</pubDate></item><item><title>风险降低80%：礼来Bamlanivimab预防养老人员新冠肺炎效果显著</title><link>https://mp.weixin.qq.com/s/DQzfpk4CovJjXSm-vYqGiQ</link><description></description><content:encoded><![CDATA[风险降低80%：礼来Bamlanivimab预防养老人员新冠肺炎效果显著]]></content:encoded><pubDate>Fri, 22 Jan 2021 12:28:42 +0800</pubDate></item><item><title>“未发现有造假”，科技部通报论文造假调查情况</title><link>https://mp.weixin.qq.com/s/kOT1YCetSNjC_QdqbN_HgA</link><description></description><content:encoded><![CDATA[“未发现有造假”，科技部通报论文造假调查情况]]></content:encoded><pubDate>Fri, 22 Jan 2021 12:28:42 +0800</pubDate></item><item><title>拜登的“战时抗疫计划”，上任两天连发14条疫情防控行政令</title><link>https://mp.weixin.qq.com/s/m8xDAkCk3G3Ws0XXPE6BOQ</link><description></description><content:encoded><![CDATA[拜登的“战时抗疫计划”，上任两天连发14条疫情防控行政令]]></content:encoded><pubDate>Fri, 22 Jan 2021 12:28:42 +0800</pubDate></item><item><title>股价上涨200％，Aclaris类风湿关节炎新药临床试验获积极数据</title><link>https://mp.weixin.qq.com/s/Ug8fb605gXeBvvR0g6UHvg</link><description></description><content:encoded><![CDATA[股价上涨200％，Aclaris类风湿关节炎新药临床试验获积极数据]]></content:encoded><pubDate>Thu, 21 Jan 2021 13:12:53 +0800</pubDate></item><item><title>《2021版生物制药小编精选文章汇编》 发布！还有有机会见到你最好奇的小编</title><link>https://mp.weixin.qq.com/s/_Wlxjzzqe1Dzh5a-MhUT8Q</link><description></description><content:encoded><![CDATA[《2021版生物制药小编精选文章汇编》 发布！还有有机会见到你最好奇的小编]]></content:encoded><pubDate>Thu, 21 Jan 2021 13:12:53 +0800</pubDate></item><item><title>10年来首个！HER2靶向药物Enhertu获FDA批准用于胃癌患者</title><link>https://mp.weixin.qq.com/s/4JhWfI0qSPnsuANecJHs5w</link><description></description><content:encoded><![CDATA[10年来首个！HER2靶向药物Enhertu获FDA批准用于胃癌患者]]></content:encoded><pubDate>Thu, 21 Jan 2021 13:12:53 +0800</pubDate></item><item><title>2021上半年10项值得关注的临床研究</title><link>https://mp.weixin.qq.com/s/n937CPQFDaGaI_-ZEkKvOA</link><description></description><content:encoded><![CDATA[2021上半年10项值得关注的临床研究]]></content:encoded><pubDate>Wed, 20 Jan 2021 12:05:17 +0800</pubDate></item><item><title>CD47-SIRPα轴肿瘤免疫疗法-靶向SIRPα</title><link>https://mp.weixin.qq.com/s/NV_M3jhBJtcqxHHYgXmXSQ</link><description></description><content:encoded><![CDATA[CD47-SIRPα轴肿瘤免疫疗法-靶向SIRPα]]></content:encoded><pubDate>Wed, 20 Jan 2021 12:05:17 +0800</pubDate></item><item><title>美国总统交接前夜，这是你在白宫之外能看到最全面的【曲速行动】</title><link>https://mp.weixin.qq.com/s/_SJ2HzM3WyP9BAgQazzCMA</link><description></description><content:encoded><![CDATA[美国总统交接前夜，这是你在白宫之外能看到最全面的【曲速行动】]]></content:encoded><pubDate>Wed, 20 Jan 2021 12:05:17 +0800</pubDate></item><item><title>双抗领域新动向，礼来与Merus达成16亿美元合作</title><link>https://mp.weixin.qq.com/s/_4yJUFH3djY6C_HYxfFrsQ</link><description></description><content:encoded><![CDATA[双抗领域新动向，礼来与Merus达成16亿美元合作]]></content:encoded><pubDate>Wed, 20 Jan 2021 12:05:17 +0800</pubDate></item></channel></rss>